AR106645A1 - THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS - Google Patents

THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Info

Publication number
AR106645A1
AR106645A1 ARP160103426A ARP160103426A AR106645A1 AR 106645 A1 AR106645 A1 AR 106645A1 AR P160103426 A ARP160103426 A AR P160103426A AR P160103426 A ARP160103426 A AR P160103426A AR 106645 A1 AR106645 A1 AR 106645A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
acceptable salt
treatment
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
ARP160103426A
Other languages
Spanish (es)
Inventor
M Koziara Joanna
Hong Lei
Micah Collman Benjamin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR106645A1 publication Critical patent/AR106645A1/en

Links

Abstract

Forma de dosificación oral sólida, que comprende un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma, y emtricitabina o una sal farmacéuticamente aceptable de la misma. Reivindicación 31: Un método para producir un comprimido de cualquiera de las reivindicaciones anteriores, en donde el método comprende (a) comprimir el compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo como primera capa, y (b) comprimir la tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma y emtricitabina o una sal farmacéuticamente aceptable de la misma como una segunda capa. Reivindicación 34: La primera capa que puede obtenerse mediante el método de la reivindicación 31. Reivindicación 35: La segunda capa que puede obtenerse mediante el método de la reivindicación 31. Reivindicación 36: Un kit que comprende (a) un comprimido que comprende un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma, y emtricitabina o una sal farmacéuticamente aceptable de la misma, y (b) un desecante.Solid oral dosage form, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof. Claim 31: A method of producing a tablet of any of the preceding claims, wherein the method comprises (a) compressing the compound of formula (1) or a pharmaceutically acceptable salt thereof as the first layer, and (b) compressing the tenofovir alafenamide or a pharmaceutically acceptable salt thereof and emtricitabine or a pharmaceutically acceptable salt thereof as a second layer. Claim 34: The first layer that can be obtained by the method of claim 31. Claim 35: The second layer that can be obtained by the method of claim 31. Claim 36: A kit comprising (a) a tablet comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof, and (b) a desiccant.

ARP160103426A 2015-11-09 2016-11-10 THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS AR106645A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562253042P 2015-11-09 2015-11-09

Publications (1)

Publication Number Publication Date
AR106645A1 true AR106645A1 (en) 2018-02-07

Family

ID=61247547

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103426A AR106645A1 (en) 2015-11-09 2016-11-10 THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Country Status (1)

Country Link
AR (1) AR106645A1 (en)

Similar Documents

Publication Publication Date Title
CO2018004776A2 (en) Therapeutic compositions for the treatment of human immunodeficiency virus
CY1120939T1 (en) COMBINATION OF REGORAFENIB AND ACETYLSALYLIC ACID FOR THE TREATMENT OF COLON CANCER
ECSP17084331A (en) PHARMACEUTICAL FORMULATIONS
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
IL285899A (en) Pharmaceutical dosage form for application to mucous membranes and methods for producing same
EA201692043A1 (en) DOSAGE FORM IMMUNODEPRESSANT
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201700356A1 (en) NEW CYCLOPROPANBENZOFURANILPYRIDOPYRAZINDIONS
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
WO2015179823A8 (en) Lung localized inhibitors of alpha(v)beta 6
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
AR110374A1 (en) DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING
AR106645A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
BR112018006206A2 (en) composition, use of a combination, pharmaceutical fixed dosage form, fixed dosage combination, packaging, and use of a fixed dose combination
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
CU20180036A7 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
EA201992754A1 (en) PHARMACEUTICAL COMPOSITIONS
TR201713326A2 (en) Production Method for Formulations Containing Rivaroxaban
TR201713325A2 (en) PRODUCTION METHOD FOR FORMULATIONS CONTAINING RIVAROXABAN
EA201892675A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ETHEPLIRSEN
ECSP17008187A (en) PHARMACEUTICAL DOSAGE FORMS

Legal Events

Date Code Title Description
FB Suspension of granting procedure